rs796052908
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_002693.3(POLG):βc.1270_1271delβ(p.Leu424GlyfsTer29) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,613,734 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 33)
Exomes π: 0.0000021 ( 0 hom. )
Consequence
POLG
NM_002693.3 frameshift
NM_002693.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 8.86
Genes affected
POLG (HGNC:9179): (DNA polymerase gamma, catalytic subunit) Mitochondrial DNA polymerase is heterotrimeric, consisting of a homodimer of accessory subunits plus a catalytic subunit. The protein encoded by this gene is the catalytic subunit of mitochondrial DNA polymerase. The encoded protein contains a polyglutamine tract near its N-terminus that may be polymorphic. Defects in this gene are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 15-89327328-CAG-C is Pathogenic according to our data. Variant chr15-89327328-CAG-C is described in ClinVar as [Pathogenic]. Clinvar id is 206608.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr15-89327328-CAG-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLG | NM_002693.3 | c.1270_1271del | p.Leu424GlyfsTer29 | frameshift_variant | 7/23 | ENST00000268124.11 | NP_002684.1 | |
POLGARF | NM_001406557.1 | c.*542_*543del | 3_prime_UTR_variant | 7/23 | NP_001393486.1 | |||
POLG | NM_001126131.2 | c.1270_1271del | p.Leu424GlyfsTer29 | frameshift_variant | 7/23 | NP_001119603.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLG | ENST00000268124.11 | c.1270_1271del | p.Leu424GlyfsTer29 | frameshift_variant | 7/23 | 1 | NM_002693.3 | ENSP00000268124 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152224Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152224
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250710Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135686
GnomAD3 exomes
AF:
AC:
1
AN:
250710
Hom.:
AF XY:
AC XY:
1
AN XY:
135686
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461510Hom.: 0 AF XY: 0.00000413 AC XY: 3AN XY: 727056
GnomAD4 exome
AF:
AC:
3
AN:
1461510
Hom.:
AF XY:
AC XY:
3
AN XY:
727056
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152224Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74374
GnomAD4 genome
AF:
AC:
2
AN:
152224
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74374
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Progressive sclerosing poliodystrophy Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 03, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine | Oct 01, 2018 | The NM_002693.2:c.1270_1271del (NP_002684.1:p.Leu424GlyfsTer29) [GRCH38: NC_000015.10:g.89327331_89327332del] variant in POLG gene is interpretated to be a Pathogenic based on ACMG guidelines (PMID: 25741868). This variant has been reported in PMID:12707443 . This variant meets the following evidence codes reported in the ACMG-guideline. PVS1:This variant is a predicted null variant in POLG where loss of function is a known mechanism of disease. PM2:This variant is absent in key population databases. PM3:Detected in trans with a pathogenic variant for Mitochondrial DNA depletion syndrome 4A (Alpers type) which is a recessive disorder. PM4:This variant causes alteration in the length of expressed protein. PP5:Reputable source(s) suggest that the variant is pathogenic. Based on the evidence criteria codes applied, the variant is suggested to be Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change creates a premature translational stop signal (p.Leu424Glyfs*29) in the POLG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POLG are known to be pathogenic (PMID: 18546365). This variant is present in population databases (rs796052908, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with autosomal recessive POLG-related conditions (PMID: 12707443, 18546365). ClinVar contains an entry for this variant (Variation ID: 206608). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 05, 2017 | c.1270_1271delCT: p.Leu424GlyfsX29 (L424Gfsx29) in exon 7 of the POLG gene (NM_002693.2). The normal sequence with the bases that are deleted in braces is: GACT{CT}GGCC.The c.1270_1271delCT mutation in the POLG gene has been reported in a child with Alpers syndrome and in an individual with adult-onset progressive external ophthalmoplegia (PEO) and multiple mtDNA deletions, both of whom had a second identified mutation in the POLG gene (Wong et al., 2008; Agostino et al., 2003). The deletion causes a frameshift starting with codon Leucine 424, changes this amino acid to a Glycine residue and creates a premature Stop codon at position 29 of the new reading frame, denoted p.Leu424GlyfsX29. This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The variant is found in INFANT-EPI panel(s). - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 07, 2021 | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in trans with a pathogenic POLG variant in at least one individual with clinical features associated with this gene. - |
Generalized epilepsy;C0028754:Obesity;C0557874:Global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Claritas Genomics | Nov 28, 2016 | The c.1270_1271delCT (p.Leu424Glyfs*29) missense variant in the POLG gene is previously reported in the literature and is expected to be causative of disease, typically as a recessive disorder. Homozygous or compound heterozygous pathogenic variants in this gene are associated with a range of mitochondrial conditions including, Alpers-Huttenlocher syndrome, childhood myocerebrohepatopathy syndrome (MCHS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), mitochondrial DNA depletion syndrome 4B (MNGIE type), mitochondrial ataxia neuropathy spectrum (includes SANDO and SCAE) and progressive external ophthalmoplegia. Progressive external ophthalmoplegia can also be inherited in an autosomal dominant manner. These conditions are known to have variable expressivity, including a wide range in age of onset as well as reduced penetrance. This deletion of two basepairs results in a shift in the reading frame at position p.Leu424 and introduces a premature stop codon 28 positions downstream, which is predicted to result in protein truncation or nonsense mediated decay. It has been reported in the compound heterozygous state in one individual with adult-onset progressive external ophthalmoplegia and one child with Alpers syndrome. It has not been observed in the 1000 Genomes, ExAC, or NHLBI Exome Sequencing Project control databases. Therefore, due to the predicted loss-of-function effect of the variant and prior reports in the literature, it is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at